

Aktuelle Datenlage zur medikamentösen Osteoprotektion bei urologischen Tumoren

Christian Thomas

Literatur

1. Goh P et al. New multidisciplinary prostate bone metastases clinic: first of its kind in Canada. *Curr Oncol* 2007; 14: 9–12
2. El-Amm J und Aragon-Ching JB. Targeting Bone Metastases in Metastatic Castration-Resistant Prostate Cancer. *Clin Med Insights Oncol* 2016; 10: 11–9
3. Saad F et al. A randomized, placebo-controlled trial fo zoledronic acid in patients with hormone-refractory metastatic prostate cancer. *J Natl Cancer Inst* 2022; 94: 1458–68
4. Zometa | European Medicines Agency - European Union.
<https://www.ema.europa.eu/en/medicines/human/EPAR/zometa>
5. Fizazi K et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. *Lancet* 2011; 377: 813–22
6. Xgeva | European Medicines Agency - European Union.
<https://www.ema.europa.eu/en/medicines/human/EPAR/xgeva>
7. Yarom N et al. Medication-Related Osteonecrosis of the Jaw: MASCC/ISOO/ASCO Clinical Practice Guideline: *J Clin Oncol* 2019; 37: 2270–90
8. Vescovi P et al. Bisphosphonates-related osteonecrosis of the jaws: a concise review of the literature and a report of a single-centre experience with 151 patients. *J Oral Pathol Med* 2012; 41: 214–21
9. Stopeck AT et al. Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer. *Support Care Cancer* 2016; 24: 447–55
10. S3-Leitlinie Prostatakarzinom. https://www.leitlinienprogramm-onkologie.de/fileadmin/user_upload/Downloads/Leitlinien/Prostatakarzinom/Version_6/LL_Prostatakarzinom_Langversion_6.2.pdf
11. Himmelstein AL et al. Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases: A Randomized Clinical Trial. *JAMA* 2017; 317: 48–58
12. Smith MR et al. Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance). *J Clin Oncol* 2014; 32: 1143–50
13. Adler RA. Management of osteoporosis in men on androgen deprivation therapy. *Maturitas* 2011; 68: 143–7
14. Smith MR et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. *N Engl J Med* 2009; 361: 745–55
15. Aclasta | EPAR summary for the public.
https://www.ema.europa.eu/en/documents/overview/aclasta-epar-summary-public_en.pdf

16. Smith MR et al. Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer. *N Engl J Med* 2018; 378: 1408–18
17. Zaghoul MS et al. A prospective, randomized, placebo-controlled trial of zoledronic acid in bony metastatic bladder cancer. *Int J Clin Oncol* 2010; 15: 382–9
18. Henry DH et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. *J Clin Oncol* 2011; 29: 1125–32
19. Rosen LS et al. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial--the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. *J Clin Oncol* 2003; 21: 3150–7